Valuation: GlaxoSmithKline Pakistan Limited

Market Cap 112B 404M 353M 326M 300M 568M 38.89B 577M 3.89B 1.53B 19.01B 1.52B 1.48B 65.51B P/E 2026 *
10.2x
P/E 2027 * 8.73x
Enterprise Value 112B 404M 353M 326M 300M 568M 38.89B 577M 3.89B 1.53B 19.01B 1.52B 1.48B 65.51B EV / Sales 2026 *
1.63x
EV / Sales 2027 * 1.51x
Free-Float
16.89%
Yield 2026 *
5.21%
Yield 2027 * 5.9%
06-08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Chief Financial Officer, Effective June 30, 2026 CI
06-08 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Executive Director of the Board of Directors, Effective June 30, 2026 CI
06-01 GlaxoSmithKline Pakistan Limited Announces Resignation of Ana Paula De Freitas Passos as Non-Executive Director, Effective May 31, 2026 CI
04-30 GlaxoSmithkline Pakistan Limited Approves Final Cash Dividend for the Year Ended 31 December, 2025 CI
04-30 GlaxoSmithkline Pakistan Limited Approves Board Elections, Effective May 25, 2026 CI
04-27 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-09 GlaxoSmithKline Pakistan Limited Proposes Final Cash Dividend for the Financial Year Ended 31 December 2025 CI
04-07 GlaxoSmithKline Pakistan Limited Announces Board Changes CI
03-31 GlaxoSmithKline Pakistan Limited Announces Resignation of Lai Kuen Goh as Chairperson and Non-Executive Director, with Effect from March 31, 2026 CI
03-26 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
24/10/25 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
02/09/25 GlaxoSmithKline Pakistan Limited Declares Interim Cash Dividend for the Half Year Ended June 30, 2025 CI
26/08/25 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
1 day-0.10%
1 week-4.97%
Current month-4.76%
1 month-6.85%
3 months-6.97%
6 months-15.47%
Current year-9.53%
1 week 349
Extreme 349
376.5
1 month 349
Extreme 349
393
Current year 293.09
Extreme 293.09
459.27
1 year 293.09
Extreme 293.09
459.94
3 years 68
Extreme 68
481
5 years 68
Extreme 68
481
10 years 68
Extreme 68
481
Manager TitleAgeSince
Chief Executive Officer - 01/03/2020
Director of Finance/CFO - 01/06/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 07/05/2011
Director/Board Member - 05/12/2018
Director/Board Member 72 02/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.10%-4.97%-9.64%+339.21% 404M
+1.67%-3.59%+48.55%+162.39% 1,031B
+1.46%-2.22%+53.75%+59.27% 595B
+2.48%+0.11%+31.27%+85.55% 431B
-0.32%-1.55%+28.92%+23.15% 326B
+0.64%-1.01%+29.35%+44.89% 277B
-0.19%-5.98%+20.31%+23.10% 263B
+1.85%+5.33%-22.23%-37.09% 224B
+1.96%+0.93%+22.73%+61.08% 193B
+1.17%-1.06%+21.44%+72.18% 164B
Average +1.03%-3.89%+22.45%+83.37% 350.47B
Weighted average by Cap. +1.26%-4.31%+34.63%+80.22%

Financials

2026 *2027 *
Net sales 68.81B 248M 217M 200M 184M 348M 23.83B 354M 2.38B 936M 11.65B 930M 910M 40.14B 74.58B 268M 235M 216M 199M 377M 25.82B 383M 2.58B 1.01B 12.62B 1.01B 986M 43.5B
Net income 10.49B 37.75M 33M 30.45M 27.99M 53.03M 3.63B 53.94M 363M 143M 1.78B 142M 139M 6.12B 12.42B 44.7M 39.08M 36.05M 33.14M 62.79M 4.3B 63.86M 430M 169M 2.1B 168M 164M 7.25B
Net Debt - -
Logo GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology, and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty, and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate, and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
Employees
1,606
Date Price Change Volume
15/07/26 PKR 352.64 -0.10% 231,416
14/07/26 PKR 353.00 -3.57% 746,000
13/07/26 PKR 366.07 -1.86% 187,726
10/07/26 PKR 373.01 +0.75% 187,081
09/07/26 PKR 370.22 -0.23% 348,661
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
352.64PKR
Average target price
517.50PKR
Spread / Average Target
+46.75%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLAXO Stock